 5. Any diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of any study medication Erlotinib,Capecitabine or that might affect the interpretation of the results or render the subject at high risk from treatment complications. 